Lysogene Reports its Cash Position as of 30 June 2021

Lysogene Reports its Cash Position as of 30 June 2021 150 150 Lysogene
  • Cash and cash equivalents of €15.0 million[1] as of 30 June 2021

[1] Unaudited figure

Paris, France — 23 July 2021 at 08:00 am CET — Lysogene (FR0013233475 – LYS), a phase 3 gene therapy platform Company targeting central nervous system (CNS) diseases, today reports its cash position as of 30 June 2021.

As of 30 June 2021, cash and cash equivalents amounted to €15.0 million1 (compared to €20.0 million as of 31 March 2021). On 28 July 2021, Lysogene will make a $2.8 million (approx. €2.4 million[2]) payment following a commercial dispute with an industrial partner for which the maximum estimated risk was $5.0 million (approx. €4.2 million2). A remaining provision of €1.2 million was recorded in the 2020 financial statements.

Stéphane Durant des Aulnois, Chief Financial Officer of Lysogene commented: “The strong financial discipline implemented in the company helped us protect our cash in the first half and largely anticipate the outcome of the dispute. As a result, our financial visibility still runs into the first half of 2022, and we are actively evaluating different financing options to extend it.”

About Lysogene

Lysogene is a gene therapy Company focused on the treatment of orphan diseases of the central nervous system (CNS). The Company has built a unique capability to enable a delivery of gene therapies to the CNS to treat lysosomal diseases and other genetic disorders of the CNS. A phase 2/3 clinical trial in MPS IIIA in partnership with Sarepta Therapeutics, Inc. is ongoing. An adaptive clinical trial in GM1 gangliosidosis is ongoing. In accordance with the agreements signed between Lysogene and Sarepta Therapeutics, Inc., Sarepta Therapeutics, Inc. will hold exclusive commercial rights to LYS-SAF302 in the United States and markets outside Europe; and Lysogene will maintain commercial exclusivity of LYS-SAF302 in Europe. Lysogene has also entered into an exclusive worldwide license agreement with SATT Conectus for a gene therapy candidate for the treatment of the Fragile X syndrome, a genetic disease related to autism.

Forward Looking Statement    

This press release may contain certain forward-looking statements, especially on the Company’s progress of its clinical trials and cash runway. Although the Company believes its expectations are based on reasonable assumptions, all statements other than statements of historical fact included in this press release about future events are subject to (i) change without notice, (ii) factors beyond the Company’s control, (iii) clinical trial results, (iv) increased manufacturing costs and (v) potential claims on its products. These statements may include, without limitation, any statements preceded by, followed by or including words such as “target,” “believe,” “expect,” “aim,” “intend,” “may,” “anticipate,” “estimate,” “plan,” “objective”, “project,” “will,” “can have,” “likely,” “should,” “would,” “could” and other words and terms of similar meaning or the negative thereof. Forward-looking statements are subject to inherent risks and uncertainties beyond the Company’s control that could cause the Company’s actual results, performance or achievements to be materially different from the expected results, performance or achievements expressed or implied by such forward-looking statements. A further list and description of these risks, uncertainties and other risks can be found in the Company’s regulatory filings with the French Autorité des Marchés Financiers, including in the 2020 universal registration document, registered with the French Markets Authorities on April 12, 2021, under number D.21-0296, and future filings and reports by the Company. Furthermore, these forward-looking statements are only as of the date of this press release. Readers are cautioned not to place undue reliance on these forward-looking statements. Except as required by law, the Company assumes no obligation to update these forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in the forward-looking statements, even if new information becomes available in the future. If the Company updates one or more forward-looking statements, no inference should be drawn that it will or will not make additional updates with respect to those or other forward-looking statements.

This press release has been prepared in both French and English. In the event of any differences between the two texts, the French language version shall supersede.

Stéphane Durant des Aulnois
Directeur Administratif et Financier
+ 33 1 41 43 03 99

[1] Unaudited figure

[2] At EUR/USD exchange rate of 1.1766 on 19 July 2021

Lysogene COVID-19 update

Get In Touch

Don’t hesitate to contact us if you need more help.